Current studentsExisting staffContact us
 

Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis

Simple item page
dc.contributor.authorSafaeian, R.
dc.contributor.authorHowarth, G.S.
dc.contributor.authorLawrance, I.C.
dc.contributor.authorTrinder, D.
dc.contributor.authorMashtoub, S.
dc.date.issued2019
dc.description.abstractOBJECTIVE:Ulcerative colitis (UC) is characterized by mucosal inflammation and ulceration of the large intestine. Emu Oil (EO) has been reported to protect the intestine against mucositis, NSAID-enteropathy, UC-associated colorectal cancer and acute UC. We aimed to determine whether EO could reduce the severity chronic UC in mice. METHODS:Female C57BL/6 mice (n = 10/group) were orally administered (gavage) water (Groups 1-2) or EO (Groups 3: low dose-80 µl and 4: high dose-160 µl), thrice weekly. Group 1 mice consumed plain drinking water throughout the trial. Groups 2-4 mice underwent two cycles [each consisting of seven days dextran sulfate sodium (DSS; 2% w/v) and 14 days water], followed by a third DSS week. All mice were euthanized two days later (day 51). Bodyweight, disease activity index (DAI), burrowing activity, myeloperoxidase activity, crypt depth and histologically assessed damage severity were assessed. p < .05 was considered significant. RESULTS:DSS decreased bodyweight and increased DAI compared to normal controls (p < .05), which was partially attenuated by both EO doses (p < .05). Burrowing activity was impaired in DSS-controls compared to normal controls (days 27 and 40); an effect prevented by both EO doses (p < .05). DSS increased colonic myeloperoxidase activity and crypt depth compared to controls (p < .05), with no significant EO effect. Moreover, DSS increased colonic damage severity compared to normal controls (p < .001). Importantly, both EO doses decreased distal colonic damage severity compared to DSS-controls (p < .001). CONCLUSIONS:Emu Oil attenuated clinically- and histologically-assessed disease severity in a mouse model of chronic UC. Emu Oil demonstrates promise as an adjunct to conventional treatment options for UC management.
dc.description.statementofresponsibilityRomina Safaeian, Gordon S. Howarth, Ian C. Lawrance, Debbie Trinder and Suzanne Mashtoub
dc.identifier.citationScandinavian Journal of Gastroenterology, 2019; 31(3):273-280
dc.identifier.doi10.1080/00365521.2019.1581253
dc.identifier.issn0036-5521
dc.identifier.issn1502-7708
dc.identifier.orcidSafaeian, R. [0000-0001-7559-936X]
dc.identifier.orcidHowarth, G.S. [0000-0001-6979-6084]
dc.identifier.orcidMashtoub, S. [0000-0001-7308-8371]
dc.identifier.urihttp://hdl.handle.net/2440/120178
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.grantNHMRC
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1020437
dc.rights© 2019 Informa UK Limited, trading as Taylor & Francis Group
dc.source.urihttps://doi.org/10.1080/00365521.2019.1581253
dc.subjectEmu Oil
dc.subjectUlcerative colitis
dc.subjectchronic
dc.subjectinflammatory bowel disease
dc.subjectmice
dc.titleEmu Oil reduces disease severity in a mouse model of chronic ulcerative colitis
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications